Antares Pharma (NASDAQ: ATRS) vs PetVivo (OTCMKTS: PETV) Stock Comparison

Antares Pharma (NASDAQ: ATRS - Get Rating) and Pet Vivo (OTCMKTS: PETV - Get Rating) are both small-cap medical organizations. In this article, we compare the two companies based on risk, institutional ownership, analyst recommendations, earnings, profitability, valuation, and returns.

Valuation and Earnings

Here is a comparison of Antares Pharma and Pet Vivo's gross revenue, profit per share (EPS), and valuation:

• Antares Pharma: $183.98 million gross revenue, price-to-sales ratio of 3.61, net income of $46.29 million, EPS of $0.27, P/E ratio of 14.44.
• Pet Vivo: $10,000 gross revenue, price-to-sales ratio of 1,612.88, net loss of $3.52 million, EPS of -$0.41, P/E ratio of -4.02.

Antares Pharma has higher revenue and profit than Pet Vivo. However, Pet Vivo has a lower price-to-earnings ratio, indicating it might be the more affordable stock currently.

Analyst Recommendations

Analysts have rated both stocks:

• Antares Pharma: 2 buy ratings, no sell or hold ratings, with a rating score of 3.00.
• Pet Vivo: 1 buy rating, no sell or hold ratings, with a rating score of 3.00.

Antares Pharma has a target price of $6.00, indicating a potential upside of 53.85%. Pet Vivo has a target price of $7.00, indicating a potential upside of 324.24%. This suggests analysts see greater upside in Pet Vivo.

Profitability

Comparison of profitability metrics:

• Antares Pharma: 25.16% net margins, 12.33% return on equity, 7.83% return on assets.
• Pet Vivo: -5,480.00% net margins, -100.42% return on equity, -70.55% return on assets.

Volatility and Risk

Both companies exhibit volatility in their stock prices:

• Antares Pharma: Beta of 1.48, indicating the stock price is 48% more volatile than the S&P 500.
• Pet Vivo: Beta of 1.9, indicating the stock price is 90% more volatile than the S&P 500.

Insider and Institutional Ownership

Ownership statistics for both companies:

• Antares Pharma: 48.6% institutional ownership, 5.9% insider ownership.
• Pet Vivo: 12.7% institutional ownership, 35.3% insider ownership.

Higher institutional ownership generally signals confidence from large investors. Antares Pharma has significantly more institutional ownership, while Pet Vivo has greater insider ownership.

Conclusion

Antares Pharma outperforms Pet Vivo on 9 out of the 13 comparison factors. However, with higher potential upside and strong insider ownership, Pet Vivo could be an intriguing speculative investment.

Company Profiles

Antares Pharma (Get Rating)

Antares Pharma, Inc. is a combination drug-device company involved in developing and commercializing self-administered parenteral pharmaceutical products. Key products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is based in Ewing, NJ.

Pet Vivo (Get Rating)

Pet Vivo Holdings, Inc. is a veterinary biotech and biomedical device company. It specializes in adapting human biotech and medical technology into products for the veterinary market. The company’s flagship product, Kush, is an intra-articular injection aimed at treating osteoarthritis in companion animals. Pet Vivo was founded in 2009 and is headquartered in Minneapolis, MN.

Martin Shkreli Banned from Pharmaceutical Industry Over Daraprim Price Hike

Shamed medication organization leader Martin Shkreli, criticized as the "Pharma Bro," was prohibited from truly carrying on with work again in the drug business, an adjudicator requested on Friday.

Shkreli was likewise requested to pay $64.6 million in benefits he scored from climbing the cost of the medication Daraprim, U.S. Area Court Judge Denise Cote administered in New York.

The court request is attached to a claim, recorded by the Federal Trade Commission and a few states, including New York and California, that blamed the detained Shkreli for monopolistic conduct.

"Shkreli is at risk on each of the cases introduced in this activity. A directive will give prohibiting him for life from taking an interest in the drug business in any way," Cote wrote in her decision.

"He is requested to pay the offended party states $64.6 million in spewing."

As CEO of Turing Pharmaceuticals - later Vyera - Shkreli expanded the cost of Daraprim from $13.50 to $750 per pill, subsequent to acquiring exclusive rights to the many years-old medication in 2015. Daraprim is required by those experiencing an uncommon parasitic infection that strikes AIDS patients, malignant growth casualties, and pregnant ladies.

"Envy, insatiability, desire, and disdain,' don't simply 'separate,' yet they clearly motivated Mr. Shkreli and his partner to illicitly lift the cost of life-saving medication as Americans' experiences remained in a precarious situation," New York Attorney General James said in a proclamation.

In any case, Shkreli is better known in mainstream society for his snide, unashamed persona that procured him the "Pharma Bro" moniker and ridicule from all sides of American life.

He's currently spending time in jail for protections extortion.

"Be that as it may, Americans can relax on the grounds that Martin Shkreli is a pharma pro no more," James said. "A government court has observed that his lead was illicit, yet additionally restricted this sentenced criminal from the drug business forever and expected him to pay almost $65 million."

A lawyer for Shkreli couldn't be quickly gone after remark on Friday.

In spite of broad reaction to Shkreli, the medication organization leader never moved in an opposite direction from exposure.